"Viking Therapeutics' Weight-Loss Drug Challenges Industry Leaders"

Viking Therapeutics stock experienced a volatile week following the announcement of positive phase II clinical trial results for its weight-loss drug, VK2735, causing shares to more than double on Tuesday. Despite a subsequent 15% drop after a stock offering, the stock has seen a 322% increase since the beginning of the year. The drug's impressive weight-loss results have sparked Wall Street's interest, with analysts raising peak sales estimates and suggesting that Viking could be an acquisition target for big pharmaceutical companies.